Innate Pharma S.A. (NASDAQ:IPHA – Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 59,700 shares, a decline of 8.3% from the August 31st total of 65,100 shares. Based on an average daily trading volume, of 6,600 shares, the days-to-cover ratio is currently 9.0 days.
Innate Pharma Trading Up 4.1 %
NASDAQ:IPHA opened at $2.29 on Tuesday. Innate Pharma has a one year low of $1.81 and a one year high of $3.15. The company’s 50-day simple moving average is $2.23 and its 200 day simple moving average is $2.37. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.92 and a quick ratio of 3.73.
Analyst Ratings Changes
Several brokerages have recently issued reports on IPHA. HC Wainwright reissued a “buy” rating and issued a $11.50 target price on shares of Innate Pharma in a research report on Friday, September 13th. Evercore ISI raised Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th.
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Read More
- Five stocks we like better than Innate Pharma
- How to Calculate Retirement Income: MarketBeat’s Calculator
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Investing In Automotive Stocks
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How to Evaluate a Stock Before Buying
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
